Kevin Grogan is the Managing Editor Europe at Commercial. He specializes in a diverse range of topics, including medicine and healthcare, alternative medicine, and business economics, with a particular focus on medical technology and diagnostics. Kevin's insights and analyses have been featured in Informa and Citeline.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kevin Grogan's articles predominantly focus on the healthcare and pharmaceutical industries, specifically covering press releases, private sector announcements, industry-specific news, and government announcements. His coverage also includes scientific topics related to drug development and biotech sectors.
Given this focus, Kevin is likely to be interested in receiving pitches that provide insights into new drug developments, clinical trials advancements, or significant healthcare deals. He may particularly appreciate access to exclusive data or expert commentary from industry professionals with insider knowledge of recent developments within the pharmaceutical field.
It's clear that Kevin has a strong interest in both scientific breakthroughs and business-related news within the pharmaceutical and biotech sectors. Therefore, individuals or organizations aiming to reach out should consider offering unique angles on these themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
AstraZeneca has chalked up another Phase III success for Imfinzi in bladder cancer, an indication that is regarded as a key growth area for the megablockbuster immunotherapy.
The Marseille-based biotech's survival hopes are based on getting a partnership pact signed very soon for lacutamab.
Deal Snapshot: With its focus very firmly set on the US, the Swedish biotech has sold the European and MENA rights to the kidney transplant desensitization therapy to the privately -owned Brussels-headquartered company.
The pact will combine the financial firms' complementary strengths across Asia-Pacific, North America and Europe, creating an investment manager with more than $21bn in assets.
The sector has seen multiple setbacks, with some big pharmas heading for the exits, but the German major believes its heavy investments in the space will ultimately pay dividends.
By: Kevin Grogan, May By
Analysts claim the French biotech is leading the oral IBD landscape and are waiting for a mega-deal centered on the miR-124 up-regulator.
The Swiss giant has highlighted a trio of key readouts coming in the second half of the year and reiterated its commitment to gene therapy.
Once a pipeline-in-a-product hopeful, the novel drug looks set for an approval decision by the end of the year in the most common type of Gaucher's disease, following a string of clinical setbacks in other indications.
The Brussels-headquartered group has recently added Hansa's Idefirix to its portfolio, which should grow at a faster rate thanks to a strong sales network in Europe and the MENA region.
The latest results on the RET inhibitor could establish a new standard of care for a rare subset of NSCLC.
